Amaryl 4 mg Norge - norsk - Statens legemiddelverk

amaryl 4 mg

sanofi-aventis norge (3) - glimepirid - tablett - 4 mg

Amaryl 1 mg Norge - norsk - Statens legemiddelverk

amaryl 1 mg

sanofi-aventis norge (3) - glimepirid - tablett - 1 mg

Amaryl 2 mg Norge - norsk - Statens legemiddelverk

amaryl 2 mg

sanofi-aventis norge (3) - glimepirid - tablett - 2 mg

Amaryl 3 mg Norge - norsk - Statens legemiddelverk

amaryl 3 mg

sanofi-aventis norge (3) - glimepirid - tablett - 3 mg

Amaryl 2 mg Norge - norsk - Statens legemiddelverk

amaryl 2 mg

orifarm as - glimepirid - tablett - 2 mg

Amaryl 3 mg Norge - norsk - Statens legemiddelverk

amaryl 3 mg

orifarm as - glimepirid - tablett - 3 mg

Alfaxan 10 mg/ ml Norge - norsk - Statens legemiddelverk

alfaxan 10 mg/ ml

jurox (ireland) limited - alfaksalon - injeksjonsvæske, oppløsning - 10 mg/ ml

Phelinun Den europeiske union - norsk - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Oxlumo Den europeiske union - norsk - EMA (European Medicines Agency)

oxlumo

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - andre alimentary tract and metabolism products, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Inrebic Den europeiske union - norsk - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.